Tejara Capital’s Vir Biotechnology VIR Stock Holding History

Tejara Capital’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-161,789	Closed	-$1.45M	–	93
2026 Q1	$1.45M	Sell	161,789 -69,457	-30%	-$553K	0.48%	56
2025 Q4	$1.39M	Sell	231,246 -25,693	-10%	-$153K	0.33%	41
2025 Q3	$1.47M	Sell	256,939 -1,661	-0.6%	-$8.49K	0.77%	33
2025 Q2	$1.3M	Buy	258,600 +28,928	+13%	+$155K	0.6%	49
2025 Q1	$1.49M	Buy	229,672 +177,705	+342%	+$1.58M	0.57%	43
2024 Q4	$381K	Buy	+51,967	New	+$410K	0.25%	49

Other funds holding VIR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Tejara Capital's VIR Position: Q2 2026 in Review

Tejara Capital sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 161,789 shares — an estimated $1.45M sold.

Tejara Capital first reported a position in VIR in Q4 2024 and held it in 6 quarters. The position peaked at $1.49M in Q1 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Tejara Capital reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
Tejara Capital sold 161,789 Vir Biotechnology shares in Q2 2026, an estimated $1.45M.
Tejara Capital first reported a position in Vir Biotechnology in Q4 2024 and held it in 6 quarters.
Tejara Capital's Vir Biotechnology position peaked at $1.49M in Q1 2025.
237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Tejara Capital's 13F filing for Q2 2026, filed 11 Aug 2026.